Monday, March 13, 2023

MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Q4 and FY 2022 Results Call

 HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, today announced its plans to host a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2022. The call is scheduled to start at 4:30 p.m. Eastern Time on Thursday, March 16, 2023. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will review the results and discuss recent announcements, ongoing initiatives and key 2023 milestones. Interested parties should visit https://ibn.fm/IZwoX to register for and access the webcast and dial 1-877-704-4453 or 1-201-389-0920 (international) and enter conference code 13735881 to access the call. A replay will be available approximately two hours after the call and will run through June 16, as detailed in the announcement.

To view the full press release, visit https://ibn.fm/VeYQj

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html